Kura Oncology to Host Investor Event on December 10, 2022

Rhea-AI Summary

Kura Oncology has announced an investor event on December 10, 2022, at 11:15 a.m. CT, following an oral presentation of data from the KOMET-001 trial at the ASH Annual Meeting in New Orleans. This event will feature insights from Kura's management and investigators on ziftomenib, a selective menin inhibitor, currently in Phase 1/2 trials targeting acute myeloid leukemia. Attendees can register for the live webcast on Kura's website, with an archived replay available afterwards.

In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New Orleans

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will host an investor event featuring members of the Kura management team and investigators from KOMET-001, a Phase 1/2 clinical trial of ziftomenib, the Company’s potent and selective menin inhibitor. The in-person investor event and live webcast will take place on Saturday, December 10, 2022, at 11:15 a.m. CT / 12:15 p.m. ET, following an oral presentation of updated data from the KOMET-001 trial at the American Society of Hematology (ASH) Annual Meeting in New Orleans.

To register for the webcast in advance, please sign up here. The live webcast will also be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available shortly after the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) in patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia. Tipifarnib, a potent, selective and orally bioavailable FTI, has received Breakthrough Therapy Designation for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC). Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company has also initiated a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in EGFR-mutant non-small cell lung cancer. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through IND-enabling studies. For additional information, please visit Kura’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Evoke Canale
(619) 849-6005
jason.spark@evokegroup.com

FAQ

What is the date and time of Kura's investor event regarding KOMET-001?

Kura's investor event will take place on December 10, 2022, at 11:15 a.m. CT.

Where will the KOMET-001 trial data be presented?

The KOMET-001 trial data will be presented at the ASH Annual Meeting in New Orleans.

What is ziftomenib and its relevance in the KOMET-001 trial?

Ziftomenib is a potent menin inhibitor currently in a Phase 1/2 clinical trial targeting acute myeloid leukemia.

How can I register for Kura's investor event webcast?

You can register for the webcast in advance through Kura's official website.

Will there be a replay of the Kura investor event?

Yes, an archived replay of the event will be available shortly after it concludes.